Jeffrey Del Carmen serves as the Chief Commercial Officer (CCO) at Catalyst Pharmaceuticals Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for rare neurological and epileptic diseases. In his role as CCO, Del Carmen is responsible for overseeing the company's commercial strategy, sales, marketing, and market access efforts. His leadership has been instrumental in driving the successful launch and growth of Catalyst's flagship product, FIRDAPSE, a treatment for Lambert-Eaton myasthenic syndrome (LEMS). Prior to joining Catalyst Pharmaceuticals, Del Carmen held several senior leadership positions in the pharmaceutical industry. He has a proven track record of building and leading high-performing commercial teams, launching successful products, and driving revenue growth. Del Carmen's experience spans across various therapeutic areas, including neurology, rare diseases, and specialty pharmaceuticals. His strategic vision and deep understanding of the healthcare landscape have enabled him to effectively navigate complex market dynamics and deliver value to patients, healthcare providers, and shareholders. Under Del Carmen's leadership, Catalyst Pharmaceuticals has made significant strides in expanding its commercial footprint and advancing its pipeline of novel therapies. His ability to foster strong relationships with key stakeholders, including patient advocacy groups and healthcare professionals, has been crucial in raising awareness about rare neurological disorders and improving patient access to life-changing treatments. As CCO, Jeffrey Del Carmen continues to play a pivotal role in shaping the future of Catalyst Pharmaceuticals and its mission to develop and deliver innovative medicines that address unmet medical needs.